Brandon Rice says preparing an outsourced IND package takes three to six months depending on how organized the sponsor is.
“It's going to take you three to six months depending on how well organized you are”
Person
Brandon Rice is a co-founder of Weave, an AI company, and this page collects what he said on NEJM AI Grand Rounds about using AI to rebuild how drugs are submitted to regulators. He explained that preparing an outsourced Investigational New Drug application, the filing sent to the U.S. FDA before clinical trials, takes three to six months, and that a New Drug Application costs millions of dollars and takes a year or more.
Rice also described his path from a bioinformatics PhD program to starting Weave with co-founder Ari Caroline. He told the host that several Weave customers had AI-produced submissions approved by the FDA and now have those drugs in clinical trials. He said AI cannot replace a blinded human trial.
1 episodes · 21 quoted claims
Brandon Rice says preparing an outsourced IND package takes three to six months depending on how organized the sponsor is.
“It's going to take you three to six months depending on how well organized you are”
Brandon Rice says assembling a New Drug Application costs millions of dollars and takes a year or more.
“An NDA, that market application on the other side, you're talking millions of dollars and a year or more to pull that information together.”
An IND, or Investigational New Drug Application, is the submission sent to the U.S. FDA explaining a drug before clinical trials can begin.
“IND is Investigational New Drug Application. And in the United States, that is the submission that you have to send to FDA explaining your drug to them effectively”
Brandon Rice says approval of a drug typically comes 10 to 15 years after the IND, via an application often called a New Drug Application.
“the end is getting approval for the drug that typically happens 10 to 15 years later that application in many cases is called an NDA a new drug application”
Brandon Rice says the success rate for INDs is over 90%, because sponsors generally submit only when ready.
“over 90% is is what it is and that's because people put so much care and effort into putting these packages together”
Brandon Rice says an IND includes non-clinical animal and in vitro studies covering pharmacology, pharmacokinetics and toxicology.
“all of the animal studies and vitro studies that you've done to understand pharmacology, pharmacokinetics, toxicology”
Brandon Rice says the manufacturing half of an IND must show how the drug is made, tested and kept consistent from batch to batch.
“How are you gonna make the drug? How are you gonna test it? How do you know that the second and third and fourth time you make it, it's the same as the first time”
Brandon Rice says NDA paperwork was once shipped to the FDA in a semi-truck, and that electronic PDF submission kept the same volume of paper.
“it used to be that you would fill the back of a semi-truck with all of the paperwork for your NDA, that market approval application I mentioned, and you would literally ship it to FDA.”
Brandon Rice says co-founder Ari Caroline introduced him to large language models in late 2022, leading them to start Weave.
“He was the one who got me wise to LLMs. I knew the problems that I wanted to solve, the business I wanted to work on.”
Brandon Rice studied Neanderthal inheritance in modern humans in his bioinformatics PhD program before dropping out to start a company.
“I was studying Neanderthal inheritance in modern humans, which was super cool.”
Brandon Rice's first company after leaving grad school offered de novo genome assembly as a service.
“company doing de novo genome assembly as a service and that was how I got going in industry”
Brandon Rice contrasts regulation in many industries, which he likens to a fence with fines for stepping outside, with drug regulation, which he likens to a railroad.
“In many industries, it's a fence around what you're allowed to do. And if you step outside that fence, you get fined.”
Brandon Rice says the U.S. FDA is interested in applying AI and already has its own initiatives for reviewing submissions.
“Today's FDA has an appetite for AI and is very interested in figuring out how to apply these technologies to their problems”
Brandon Rice says Weave designs its software expecting AI models to keep improving, rather than patching the weaknesses of current models.
“we just expect the models to get better and eventually to get really, really good.”
Brandon Rice describes Weave's platform as the car built around AI models, which act as the engine.
“We think about the models as an engine. We're building the car.”
Brandon Rice says training custom models no longer makes sense for Weave and that trust is its main advantage.
“Training models doesn't really make sense anymore. It's passe, I think. You don't need to do that.”
Brandon Rice says establishing causality requires a blinded clinical trial in humans, which limits how much AI can speed up that stage.
“ultimately you have to establish causality here. And there's just no way that I've ever been told about or thought of that you could do that outside of a clinical trial, a blinded trial of some kind.”
Brandon Rice says China's regulatory environment is more aligned to enabling fast clinical trials, and U.S. advocates are beginning to push for similar changes.
“yes, the regulatory environment is more aligned to enabling that. And that is something that people in the U.S. are starting to advocate for and pay attention to.”
Brandon Rice says several Weave customers submitted AI-produced submissions to the FDA, had them approved, and now have those drugs in clinical trials.
“They submitted those to FDA, they've been approved and those drugs are now in clinic.”
Brandon Rice names Carl Sagan as his scientific hero for his skill at communicating science.
“Still Carl Sagan, I would say, because of the communication, the narration”
Brandon Rice compares AI to the internet, saying the dot-com era was only the first phase and AI will likewise become ordinary after a hype cycle.
“You know, the internet didn't happen in the dot-com era. That was just the first phase.”